Xvivo Perfusion AB (XVIPF)
OTHER OTC:XVIPF
XVIPF Stock Chart & Stats
$20.01
-$1.30(-2.83%)
At close: 4:00 PM EST
$20.01
-$1.30(-2.83%)
Day’s Range― - ―
52-Week Range$16.69 - $34.79
Previous CloseN/A
Volume100.00
Average Volume (3M)104.00
Market Cap
$857.16M
Enterprise Value$7.91B
Total Cash (Recent Filing)$292.09M
Total Debt (Recent Filing)$237.89M
Price to Earnings (P/E)233.6
Beta1.00
Next Earnings
Apr 24, 2026EPS Estimate
0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.11
Shares Outstanding31,499,470
10 Day Avg. Volume25
30 Day Avg. Volume104
Financial Highlights & Ratios
PEG Ratio-2.74
Price to Book (P/B)2.78
Price to Sales (P/S)7.24
P/FCF Ratio0.00
Enterprise Value/Market Cap9.23
Enterprise Value/Revenue9.74
Enterprise Value/Gross Profit14.82
Enterprise Value/Ebitda54.02
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.39
Revenue Forecast (FY)$104.35M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthLow leverage and a sizable equity cushion provide durable financial flexibility, helping fund production scaling, regulatory activities, and commercial expansion without immediate reliance on dilutive capital. This reduces execution risk and improves the company's ability to sustain multi‑quarter investments.
Recurring Consumables MomentumStrong, double‑digit organ disposable growth indicates durable pull‑through from procedures: consumables generate recurring, high‑margin revenue per transplant and strengthen predictability of cash flows as adoption of liver/kidney products broadens installed base and supports long‑term revenue resilience.
Clinical Evidence & Regulatory ProgressRobust clinical outcomes and breakthrough designations create a substantive competitive moat: demonstrable patient benefit and regulatory support accelerate hospital adoption, ease payer/provider acceptance, and underpin sustainable uptake across transplant centers as regulatory approvals progress.
Bears Say
Inconsistent Cash ConversionVolatile cash conversion and repeated negative free cash flow constrain the firm's ability to self‑fund growth and make scaling dependent on external financing or careful working‑capital management. This raises execution risk for multi‑year investments like U.S. launches and capacity expansion.
2025 Revenue & Margin DeteriorationA pronounced drop in revenue and collapse in net margin signals structural headwinds—mix shifts, higher costs, or one‑offs—that reduce earnings quality. Restoring prior margin levels will require sustained commercial execution and cost discipline, lengthening the path to durable profitability.
Regulatory Timing & Execution RiskUnclear regulatory timelines and paused PMA activity inject material timing risk into commercial rollouts, especially the U.S. heart launch. Delays can push revenue recognition, increase go‑to‑market costs, and amplify the need for sustained financing and execution over multiple quarters.
Xvivo Perfusion AB News
XVIPF FAQ
What was Xvivo Perfusion AB’s price range in the past 12 months?
Xvivo Perfusion AB lowest stock price was $16.69 and its highest was $34.79 in the past 12 months.
What is Xvivo Perfusion AB’s market cap?
Xvivo Perfusion AB’s market cap is $857.16M.
When is Xvivo Perfusion AB’s upcoming earnings report date?
Xvivo Perfusion AB’s upcoming earnings report date is Apr 24, 2026 which is in 14 days.
How were Xvivo Perfusion AB’s earnings last quarter?
Xvivo Perfusion AB released its earnings results on Jan 27, 2026. The company reported $0.112 earnings per share for the quarter, beating the consensus estimate of $0.074 by $0.039.
Is Xvivo Perfusion AB overvalued?
According to Wall Street analysts Xvivo Perfusion AB’s price is currently Overvalued.
Does Xvivo Perfusion AB pay dividends?
Xvivo Perfusion AB does not currently pay dividends.
What is Xvivo Perfusion AB’s EPS estimate?
Xvivo Perfusion AB’s EPS estimate is 0.1.
How many shares outstanding does Xvivo Perfusion AB have?
Xvivo Perfusion AB has 31,499,470 shares outstanding.
What happened to Xvivo Perfusion AB’s price movement after its last earnings report?
Xvivo Perfusion AB reported an EPS of $0.112 in its last earnings report, beating expectations of $0.074. Following the earnings report the stock price went up 1.808%.
Which hedge fund is a major shareholder of Xvivo Perfusion AB?
Currently, no hedge funds are holding shares in XVIPF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Xvivo Perfusion AB
Xvivo Perfusion AB (publ), a medical technology company, develops solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation in Sweden, the United States, North America and South America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers XVIVO System (XPS), an integrated off-the-shelf cardiac bypass system that includes various components needed to safely run normothermic ex vivo lung perfusion (EVLP); XPS Disposable Lung Kit that contains disposables and pre-packed products to suit requirement for sterility; and STEEN Solution, a buffered extracellular solution optimally designed to perfuse the isolated donor lung during EVLP. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XVIVO Silicone Tubing Set for rapid flushing of donor lungs during procurement; and XVIVO LS and XVIVO Disposable Lung Set, a device for EVLP. In addition, the company offers XVIVO Organ Chamber, a single-use sterile disposable container intended to be used as a temporary receptacle for isolated lungs in preparation for eventual transplantation into a recipient; and XVIVO Lung Cannula Set, a single-use, sterile disposable product. The company was incorporated in 1998 and is headquartered in Gothenburg, Sweden.
XVIPF Company Deck
XVIPF Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented several strong, company-defining positives: record quarterly EBITDA, first positive quarter cash flow, meaningful growth and market penetration in abdominal and liver segments, significant clinical milestones for Heart Assist (including a 76% reduction in severe PGD) and expanding EVLP service models. However, meaningful near-term challenges were also highlighted: weakness in Services, inventory write-offs depressing margins, earlier-than-expected EVLP shortfalls due to U.S. field force gaps, regulatory timing uncertainty, and currency risks. The company is taking corrective actions (hiring, partnerships, scaling production) and plans heavy investments in 2026 to support launches and future growth. On balance the clinical breakthroughs, record profitability metrics for Q4, and operational scaling progress outweigh the operational and timing challenges, but the near-term path will include planned investments and execution risk.View all XVIPF earnings summariesTechnical Analysis
Ownership Overview
―
Insiders
2.82% Mutual Funds
― Other Institutional Investors
93.95% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---